


CLAIMS

What is claimed is:

1. A compound represented by Structural Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

X¹ is -F, -Cl, -CF₃, -CN, or CH₃;

X² is -H, -F, or -Cl;

Z¹ is N or CH;

Z² is N or CR⁰;

Z³ is CH or N;

Y is -C(R⁴R⁵)-[C(R⁶R⁷)]_n-Q or -C(R⁴)=C(R⁶)-Q;

R⁰ is -H, -F, or CN;


R¹, R², and R³ are each and independently -CH₃, -CH₂F, -CF₃, -C₂H₅, -CH₂CH₂F, -CH₂CF₃; or optionally R² and R³, or R¹, R² and R³, together with the carbon atom to which they are attached, form a 3-10 membered carbocyclic ring;

R⁴ and R⁵ are each and independently -H;

R⁶ and R⁷ are each and independently -H, -OH, -CH₃, or -CF₃; or

optionally, R⁵ and R⁷ together with the carbon atoms to which they are attached form a cyclopropane ring; and

each Q is independently -C(O)OR, -OH, -CH₂OH, -S(O)R', -P(O)(OH)₂, -S(O)₂R', -S(O)₂-NR''R''', or a 5-membered heterocycle selected from the group consisting of:



JQ is -H, -OH or -CH₂OH;

R is -H or C₁₋₄ alkyl;

R' is -OH, C₁₋₄ alkyl, or -CH₂C(O)OH;

R'' is -H or -CH₃;


R''' is -H, a 3-6 membered carbocyclic ring, or C₁₋₄ alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, -OR^a and -C(O)OR^a;

R^a is -H or C₁₋₄ alkyl; and


n is 0 or 1.

2. The compound of claim 1, wherein X¹ is -F or -Cl.
3. The compound of claim 1 or 2, wherein X² is -F or -Cl.
4. The compound of any one of claims 1-3, wherein Z¹ is CH.
5. The compound of any one of claims 1-3, wherein Z¹ is N.
6. The compound of any one of claims 1-5, wherein Z² is N, C-F, or C-CN.
7. The compound of any one of claims 1-6, wherein R¹, R², and R³ are each and independently -CH₃ or -C₂H₅; or optionally R² and R³, or R¹, R² and R³, together with the carbon atom to which they are attached, form a 3-10 membered carbocyclic ring.
8. The compound of any one of claims 1-6, wherein R¹, R², and R³ are each and independently -CH₃, -CH₂F, -CF₃, or -C₂H₅; or R¹ is -CH₃, and R² and R³ together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring.
9. The compound of claim 8, wherein each of R¹, R², and R³ is independently -CH₃ or -C₂H₅; or R¹ is -CH₃, and R² and R³ together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring.
10. The compound of any one of claims 1-9, wherein:
R⁶ and R⁷ are each and independently -H, -OH, -CH₃, or -CF₃.

11. The compound of any one of claims 1-10, wherein each Q is independently $-\text{C}(\text{O})\text{OR}$, $-\text{OH}$, $-\text{CH}_2\text{OH}$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{S}(\text{O})_2-\text{NR}''\text{R}'''$, or a 5-membered heterocycle selected from the group




12. The compound of claim 11, wherein Q is $-\text{C}(\text{O})\text{OR}$, $-\text{OH}$, $-\text{S}(\text{O})_2\text{R}'$, or $-\text{S}(\text{O})_2-\text{NR}''\text{R}'''$.
13. The compound of any one of claims 1-12, wherein:
 R' is $-\text{OH}$ or $-\text{CH}_2\text{C}(\text{O})\text{OH}$;
 R'' is $-\text{H}$; and
 R''' is $-\text{H}$, a 3-6 membered carbocyclic ring, or optionally substituted C_{1-4} alkyl.
14. The compound of any one of claims 1-13, wherein R is $-\text{H}$.
15. The compound of any one of claims 1-14, wherein the compound is represented by Structural Formula II:



or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1, wherein the compound is represented by Structural Formula




III:

or a pharmaceutically acceptable salt thereof.


17. The compound of claim 16, wherein X^1 is $-F$ or $-Cl$.
18. The compound of claim 16 or 17, wherein X^2 is $-F$ or $-Cl$.
19. The compound of any one of claims 16-18, wherein Z^1 is CH .
20. The compound of any one of claims 16-18, wherein Z^1 is N .
21. The compound of any one of claims 16-20, wherein Z^2 is N , $C-F$, or $C-CN$.
22. The compound of any one of claims 16-21, wherein R^1 , R^2 , and R^3 are each and independently $-CH_3$ or $-C_2H_5$; or optionally R^2 and R^3 , or R^1 , R^2 and R^3 , together with the carbon atom to which they are attached, form a 3-10 membered carbocyclic ring.
23. The compound of any one of claims 16-21, wherein R^1 , R^2 , and R^3 are each and independently $-CH_3$, $-CH_2F$, $-CF_3$, or $-C_2H_5$; or R^1 is $-CH_3$, and R^2 and R^3 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring.
24. The compound of claim 23, wherein each of R^1 , R^2 , and R^3 is independently $-CH_3$ or $-C_2H_5$; or R^1 is $-CH_3$, and R^2 and R^3 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring.
25. The compound of any one of claims 16-24, wherein Q is $-C(O)OR$, $-OH$, $-S(O)_2R'$, or $-S(O)_2-NR''R'''$.
26. The compound of any one of claims 16-25, wherein:
 R' is $-OH$ or $-CH_2C(O)OH$;
 R'' is $-H$; and
 R''' is $-H$, a 3-6 membered carbocyclic ring, or optionally substituted C_{1-4} alkyl.

27. The compound of any one of claims 16-26, wherein R is -H.

28. The compound of any one of claims 16-27, wherein the compound is represented by Structural Formula (IV) or (V):




(IV),




(V)

or a pharmaceutically acceptable salt thereof.


29. The compound of claim 1, wherein the compound is represented by any one of Structural Formulae (VI)-(X):




(VI),




(VII),



(VIII),



(IX),



(X),


or a pharmaceutically acceptable salt thereof, wherein:

R^1 , R^2 , and R^3 are each and independently $-\text{CH}_3$, $-\text{CH}_2\text{F}$, $-\text{CF}_3$, $-\text{C}_2\text{H}_5$, $-\text{CH}_2\text{CH}_2\text{F}$, $-\text{CH}_2\text{CF}_3$; and


Ring P is a 3-6 membered carbocyclic ring.

30. The compound of claim 29, wherein X^1 is $-\text{F}$ or $-\text{Cl}$.
31. The compound of claim 29 or 30, wherein X^2 is $-\text{F}$ or $-\text{Cl}$.
32. The compound of any one of claims 29-31, wherein Z^1 is CH .
33. The compound of any one of claims 29-31, wherein Z^1 is N .
34. The compound of any one of claims 29-33, wherein Z^2 is N , C-F , or C-CN .
35. The compound of any one of claims 29-34, wherein R^1 , R^2 , and R^3 are each and independently $-\text{CH}_3$ or $-\text{C}_2\text{H}_5$.
36. The compound of any one of claims 29-35, wherein:
 R' is $-\text{OH}$ or $-\text{CH}_2\text{C}(\text{O})\text{OH}$;
 R'' is $-\text{H}$; and
 R''' is $-\text{H}$, a 3-6 membered carbocyclic ring, or optionally substituted C_{1-4} alkyl.
37. The compound of any one of claims 29-36, wherein R is $-\text{H}$.
38. The compound of claim 1, selected from any one of the compounds depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.
39. A pharmaceutical composition, comprising a compound according to any one of claims 1-38, and a pharmaceutically acceptable carrier, adjuvant or vehicle.


40. A method of inhibiting the replication of influenza viruses in a biological sample or patient, comprising the step of administering to said biological sample or patient an effective amount of a compound as described in any one of claims 1-38.
41. The method of claim 40, further comprising co-administering an additional therapeutic agent.
42. The method of claim 41, wherein the additional therapeutic agent is selected from an antiviral agent or an Influenza vaccine.
43. A method of reducing the amount of influenza viruses in a biological sample or in a patient, comprising administering to said biological sample or patient an effective amount of a compound as described in any one of claims 1-38.
44. A method of treating influenza in a patient, comprising administering to said patient an effective amount of a compound as described in any one of claims 1-38.
45. A method preparing a compound represented by Structural Formula (I):



or a pharmaceutically acceptable salt thereof, comprising the steps of:




- i) reacting compound A: (A) with compound B:



(B) to

form a compound represented by Structural Formula (XX):



(XX); and

ii) deprotecting the G group of the compound of Structural Formula (XX) under suitable conditions to form the compound of Structural Formula (I), wherein:


the variables of Structural Formulae (I) and (XX), and compounds (A) and (B) are independently as defined in any one of claims 1-38; and

L^2 is a halogen; and


when Z^1 is N, G is trityl; when Z^1 is CH, G is tosyl or trityl.

46. The method of claim 45, wherein L^2 is Br or Cl.

47. A method preparing a compound represented by Structural Formula (I):




or a pharmaceutically acceptable salt thereof, comprising the steps of:



i) reacting compound K or L:

compound D: $\text{NH}_2\text{-Z}^3((\text{CR}^1\text{R}^2\text{R}^3)\text{-Y})$ to form a compound represented by Structural Formula (XX):




(XX); and

ii) deprotecting the G group of the compound of Structural Formula (XX) under suitable conditions to form the compound of Structural Formula (I), wherein:

the variables of Structural Formulae (I) and (XX), and compounds (L), (K), and (D) are each and independently as defined in any one of claims 1-38; and


when Z¹ is N, G is trityl; when Z¹ is CH, G is tosyl or trityl.

48. A method preparing a compound represented by Structural Formula (I):




or a pharmaceutically acceptable salt thereof, comprising the steps of:

i) reacting Compound (G) with Compound (D):

(G), NH₂-Z³((CR¹R²R³)-Y (D),

under suitable conditions to form a compound represented by Structural Formula (XX):



(XX); and

ii) deprotecting the G group of the compound of Structural Formula (XX) under suitable conditions to form the compound of Structural Formula (I), wherein:


the variables of Structural Formulae (I) and (XX), and Compounds (G) and (D) are each and independently as defined in any one of claims 1-38;

L^1 is a halogen; and

when Z^1 is N, G is trityl; when Z^1 is CH, G is tosyl or trityl.

49. The method of claim 48, wherein L^1 is Br or Cl.

50. A compound represented by Structural Formula (XX) or a pharmaceutically acceptable salt thereof:




wherein the variables of Structural Formula (XX) are each and independently as defined in any one of claims 1-38; and

when Z^1 is N, G is trityl; when Z^1 is CH, G is tosyl or trityl.

CLAIMS

What is claimed is:

1. A compound of the formula



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.